Archives

The best photos of 2025

We are very fortunate at AP to be able to view thousands of fantastic images each year. It’s not easy to choose a favourite but here are a few that that stuck with us in 2025 along with images chosen by picture editors – photographs shaped by conflict, crisis and fleeting moments of humanity. The […]

JCM, Vol. 15, Pages 181: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus

JCM, Vol. 15, Pages 181: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes Mellitus Journal of Clinical Medicine doi: 10.3390/jcm15010181 Authors: Ricardo E. T. Navarrete Joana Freitas Isabel Fonseca Ana Cunha Joao Roberto Sa La Salete Martins Background: Despite the lack of formal […]

Narendra Solanki sees select opportunities in metals, GLP-1 and solar plays

Amid global uncertainty, market expert Narendra Solanki advises theme-based investing. He highlights opportunities in specific metals like steel and copper, niche pharma plays focusing on GLP-1 drug delivery mechanisms, and renewable-linked manufacturing, particularly solar pump companies benefiting from government schemes. This selective approach targets companies with cost advantages and policy support for growth.

HIMS Might be Undervalued by ~ 20%?

I valued Hims 6 months ago at ~$34/share. Back then my main thesis was that telehealth was a low-margin business, subscriber growth was fueled by gobs of marketing spend, that their fastest growing vertical (GLP-1 meds) faced regulatory hurdles, and the business competed in a fragmented and highly competitive D2C space. I decided to take […]

Weight-loss therapy set to push pharma growth

India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1 medicines, accelerating innovation through AI, and a shift towards complex generics. This transformative phase promises improved patient outcomes and positions India as a key player in global healthcare advancements.

Ozempic Is Shrinking More Than Waistlines, It’s Slashing Americans’ Food Bills

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far beyond individual health. When people in the United States begin using appetite-suppressing medications such as Ozempic and Wegovy, the effects can reach far beyond changes in body weight. New research from Cornell University suggests that […]

Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle?

Key Points Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its closest competitor. The drugmaker should continue riding this wave for the foreseeable future. 10 stocks we like better than Eli Lilly › Over the past few years, Eli Lilly (NYSE: […]

$NVO Quality GIGA-LONNNNNNNGGGGG!!!

$NVO Quality GIGA-LONNNNNNNGGGGG!!! Novo Nordisk A/S Sponsored ADR Class B BATS:NVO MrJosephTrades This is a weekly of NVO, a global leader in pharmaceuticals addressing issues like obesity, diabetes, among other things. Ever hear of Ozempic? This company makes it. They also have other products in their pipeline which intend to capitalize on these growing epidemics, […]

How weight-loss drugs are reshaping fitness gyms – Axios

How weight-loss drugs are reshaping fitness gyms  Axios 87% of Doctors Say Obesity Drugs Help Patients  동아비즈니스리뷰 | DBR Korea weighs reimbursing GLP‑1 obesity drugs amid rising prevalence and cost concerns – CHOSUNBIZ  Chosunbiz “Do You Want to Lose Weight?” “I’ll Take Wegovy”… Gyms Break Out in a Cold Sweat  아시아경제 The end of the year and the beginning […]